SYRE
Spyre Therapeutics, Inc.
Next earnings Aug 3, 2026 · consensus $-0.77 EPS
Last earnings +2.7% on 2026-05-05
$87.89
▼ -0.88%$87.89▲ +498.71%
over 1Y
L $14.68EODHDH $100.32
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-0.9%
1W-12.4%
1M+21.2%
3M+85.8%
YTD+187.4%
1Y+498.7%
Hold
Conviction
Horizon
Long (>12mo)
Street · 23 analysts
Strong Buy
A well-funded clinical-stage IBD biotech with no revenue — a binary bet on antibody trial readouts, not an analyzable business.
Revenue (FY2025) $0.00 · FY2025
Spyre Therapeutics (formerly Aeglea BioTherapeutics) is a clinical-stage biotech reshaped around a portfolio of next-generation monoclonal antibodies for inflammatory bowel disease (ulcerative colitis, Crohn's) and other immune-mediated diseases — the SPY001 (alpha-4-beta-7 integrin), SPY002 (TL1A) and SPY003 (IL-23) programs licensed from Paragon. It has no commercial product and generated zero product revenue in FY2025; the only revenue history is a small legacy gain tied to the pegzilarginase sale to Immedica, the proceeds of which largely flow to CVR holders. This is a pipeline story whose value is entirely contingent on clinical and regulatory success.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $18.7M | $2.33M | $886K | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — |
| Operating income | -$65.6M | -$84.8M | -$242M | -$209M | -$210M |
| Net income | -$65.8M | -$83.8M | -$339M | -$208M | -$155M |
| Diluted EPS | -$25.02 | -$24.86 | -$49.12 | — | — |
| Net margin | -351.1% | -3598.8% | -38238.1% | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$6.82B
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-2.2%
FCF yield-2.5%
Quality & risk
ROIC (est.)-23.1%
Free cash flow-$169M
Total debt—
Net cash$85.7M
Altman Z-Score64.41 safe
Piotroski F-Score2/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+30.3%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
- 8-K Reg FD disclosure2026-06-15
- 8-K Other event2026-06-01
- 8-K Officer / director change2026-05-29
- 8-K Earnings results2026-05-05
- 10-Q Quarterly report2026-05-05
- 8-K Material agreement2026-04-16
- 8-K Earnings results2026-04-13
- DEF 14A Proxy statement2026-04-10
- S-3 Shelf registration (potential raise)2026-02-19
Recent filings
all on EDGAR ↗4Period ending 2026-06-252026-06-26open ↗S-3ASRFiling2026-06-26open ↗144Filing2026-06-25open ↗144Filing2026-06-23open ↗4Period ending 2026-06-232026-06-23open ↗SCHEDULE 13D/AFiling2026-06-23open ↗4Period ending 2026-06-222026-06-23open ↗144Filing2026-06-22open ↗8-KPeriod ending 2026-06-152026-06-15open ↗4Period ending 2026-06-032026-06-03open ↗4Period ending 2026-06-012026-06-03open ↗4Period ending 2026-06-012026-06-03open ↗
Frequently asked
- Is Spyre Therapeutics, Inc. (SYRE) a buy?
- SYRE currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. A well-funded clinical-stage IBD biotech with no revenue — a binary bet on antibody trial readouts, not an analyzable business.
- What is Spyre Therapeutics, Inc.'s quality score?
- SYRE scores 57.717948717948715/100 (grade C) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001636282, latest 10-Q filed 2026-05-05) · EODHD · analysis by claude-code · as of 6/21/2026, 8:53:39 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.